Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Annual Meeting May 9th

<< Previous

Bullboard Posts

Next >>

Comment by SABBOBCATon Mar 10, 2023 5:30pm

102 Views

Post# 35331848

RE:RE:Annual Meeting May 9th

I view the April 4th date as a the decision point whereby leadership needs to:

A) clearly articulate where the company stands, where the science lies, what partnerships are likely to materialize, and a more detailed plan they can benchmark to for creating value.

or

B) have a NASH deal inked they will immediately show validation and drive the SP up.

baring either other these, the compensation committee and 1-2 other BoD need to go.

<< Previous

Bullboard Posts

Next >>

POET increases production capacity to meet AI demand